Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Antibodies, Monoclonal"
journalStr:"Annals of the rheumatic diseases"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%22&filter%5B%5D=journalStr%3A%22Annals+of+the+rheumatic+diseases%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%22&filter%5B%5D=journalStr%3A%22Annals+of+the+rheumatic+diseases%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Antibodies%2C+Monoclonal%22&filter%5B%5D=journalStr%3A%22Annals+of+the+rheumatic+diseases%22&lookfor=%22Antibodies%2C+Monoclonal%2C+Humanized%22&type=Subject
PubPharm (219)
1
Response to : 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al
enthalten in:
Annals of the rheumatic diseases
| 2022
von
Ozen, S.
|
De Benedetti, F.
CommentOn: Ann Rheum Dis. 2020 Oct;79(10):1362-1369. - PMID 32571870
Wird geladen...
2
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate : efficacy and safety results of a randomised controlled phase III study
enthalten in:
Annals of the rheumatic diseases
| 2022
von
Nasonov, E.
|
Fatenejad, S.
|
Feist, E.
| +8
Wird geladen...
3
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis : 16-week results from a randomised, placebo-controlled, phase 3 trial
enthalten in:
Annals of the rheumatic diseases
| 2021
von
Wei, J.
|
Kim, T.
|
Kishimoto, M.
| +54
CommentIn: Ann Rheum Dis. 2023 Jul;82(7):e168. - PMID 34172501
Wird geladen...
4
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis : results from a large US registry study
enthalten in:
Annals of the rheumatic diseases
| 2021
von
Pappas, D.
|
St John, G.
|
Etzel, C.
| +8
CommentIn: Ann Rheum Dis. 2022 Nov;81(11):e224. - PMID 33177099
Wird geladen...
5
Immune checkpoint inhibitor rechallenge in patients with immune-related myositis
enthalten in:
Annals of the rheumatic diseases
| 2019
von
Delyon, J.
|
Brunet-Possenti, F.
|
Leonard-Louis, S.
| +6
Wird geladen...
6
Response to : 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg
enthalten in:
Annals of the rheumatic diseases
| 2019
von
Morand, E.
|
Trasieva, T.
|
Berglind, A.
| +2
CommentOn: Ann Rheum Dis. 2018 May;77(5):706-713. - PMID 29420200
Wird geladen...
7
Comment on : 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al
enthalten in:
Annals of the rheumatic diseases
| 2019
von
Isenberg, D.
CommentOn: Ann Rheum Dis. 2018 May;77(5):706-713. - PMID 29420200
Wird geladen...
8
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
enthalten in:
Annals of the rheumatic diseases
| 2019
von
Dörner, T.
|
Posch, M.
|
Li, Y.
| +11
Wird geladen...
9
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
enthalten in:
Annals of the rheumatic diseases
| 2019
von
Mammen, A.
|
Rajan, A.
|
Pak, K.
| +9
Wird geladen...
10
Are the loading dose treatment groups superior to the 150 mg without loading dose group in the secukinumab FUTURE 5 study?
enthalten in:
Annals of the rheumatic diseases
| 2019
von
Matos da Cunha, B.
CommentOn: Ann Rheum Dis. 2018 Jun;77(6):890-897. - PMID 29550766
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[22]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Antibodies, Monoclonal
Filter aufheben
Zeitschrift: Annals of the rheumatic diseases
Medienart
219
Aufsätze
174
E-Artikel
174
E-Ressourcen
45
Gedruckte Aufsätze
Zeitschriftentitel
Annals of the rheumatic diseases
Thema
Antibodies, Monoclonal
219
Antibodies, Monoclonal, Humanized
179
Journal Article
165
Antirheumatic Agents
132
Research Support, Non-U.S. Gov't
131
Adalimumab
131
FYS6T7F842
129
Tumor Necrosis Factor-alpha
76
B72HH48FLU
76
Immunoglobulin G
76
Infliximab
74
Receptors, Tumor Necrosis Factor
72
Etanercept
72
OP401G7OJC
57
Multicenter Study
55
Randomized Controlled Trial
42
Methotrexate
42
YL5FZ2Y5U1
33
Letter
28
Klinische Studie
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2020-
131
2010-2019
84
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
219
Englisch
Haven't found what you're looking for?
Wird geladen...